These therapeutic strategies could be particularly effective when combined with targeted next generation sequencing of tumor samples, since genomic alterations can be detected and help to identify refractory patients with aberrations putatively activating the PI3K/Akt/mTOR pathway [47, 48]. The gene discussed is MTOR; the disease is neoplasm.